Richard Leigh-Pemberton

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial

Maurizio Fava, Michael E. Thase, J. Alexander Bodkin et al. · American Journal of Psychiatry · 2016 · 228 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Evaluation of Opioid Modulation in Major Depressive Disorder

Elliot Ehrich, Ryan Z. Turncliff, Yangchun Du et al. · Neuropsychopharmacology · 2014 · 173 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Robert T. Naismith, Annette Wundes, Tjalf Ziemssen et al. · CNS Drugs · 2020 · 130 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes et al. · Multiple Sclerosis Journal · 2019 · 64 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

Michael J. Palte, Angela Wehr, Mark Tawa et al. · Advances in Therapy · 2019 · 61 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11